Liver cancer research aims to unlock secrets of immunotherapy response

NCT ID NCT04145141

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study gathers blood, urine, stool, and tissue samples from 132 adults with primary liver cancer who are receiving or have received immunotherapy. Researchers will analyze these samples along with medical records to learn more about how liver cancer develops and responds to treatment. Participants are followed for life by phone or email, but no new treatments are given as part of this study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this research could help doctors design better, more personalized immunotherapies for liver cancer patients.
What could go wrong
This is an observational study, not a treatment trial. It collects data and samples but does not test a new therapy directly, so it may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.